Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
27 nov. 2023 03h00 HE
|
Priothera
Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global registration-enabling Phase 3...
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
09 nov. 2023 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Mastering the FDA Drug Approval Process: Strategies for Success in the US Pharmaceutical Market (February 6-7, 2024)
02 nov. 2023 07h28 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
03 oct. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Interim results for the six months ended 30 June 2023
29 sept. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
21 sept. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Global Orphan Drugs Market Research Report 2023
19 sept. 2023 05h38 HE
|
Research and Markets
Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global orphan drugs market is expected to grow...
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
25 août 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
VD Kommentarer Vår Fas III-studie, den största studien av sitt slag som någonsin genomförts, fortskrider på 88 sjukhus och i tio länder. Vi har nu rekryterat 85% av patienterna (1824 av de...
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
25 août 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the...
Orphan Drugs and Rare Diseases Conference: Life-saving Therapies, Critical Issues, and Strategies to Enhance Orphan Drug Development in near future (London, United Kingdom - October 9-10, 2023)
14 août 2023 04h13 HE
|
Research and Markets
Dublin, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases Conference" conference has been added to ResearchAndMarkets.com's offering. The 4th Annual Orphan Drugs and Rare...